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Abstract: Manganese-zinc-ferrite nanoparticles (Mn0.5Zn0.5Fe2O4, MZF-NPs) prepared by 
an improved co-precipitation method and were characterized by transmission electron 
microscopy (TEM), X-ray diffraction (XRD) and energy dispersive spectrometry (EDS). 
Then thermodynamic testing of various doses of MZF-NPs was performed in vitro. The 
cytotoxicity of the Mn0.5Zn0.5Fe2O4 nanoparticles in vitro was tested by the MTT assay. A 
nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex was made by an impregnation process. The 
complex’s shape, component, envelop rate and release rate of As2O3 were measured by 
SEM, EDS and atom fluorescence spectrometry, respectively. The therapeutic effect of 
nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex combined with magnetic fluid hyperthermia 
(MFH) on human hepatocelluar cells were evaluated in vitro by an MTT assay and flow 
cytometry. The results indicated that Mn0.5Zn0.5Fe2O4 and nanosized As2O3/Mn0.5Zn0.5Fe2O4 
complex were both prepared successfully. The Mn0.5Zn0.5Fe2O4 nanoparticles had powerful 
absorption capabilities in a high-frequency alternating electromagnetic field, and had 
strong magnetic responsiveness. Moreover, Mn0.5Zn0.5Fe2O4 didn’t show cytotoxicity in 
vitro. The therapeutic result reveals that the nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex can 
significantly inhibit the growth of hepatoma carcinoma cells. 
Keywords:  As2O3/Mn0.5Zn0.5Fe2O4 complex; preparation; anti-tumor; hepatocellular 
carcinoma cells 
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1. Introduction  
 
Current hyperthermia treatment strategies centre around the objective of preferential killing of 
malignant cells and localized heating of tissue deep inside the patient. Magnetic fluid hyperthermia 
(MFH) offers a means of doing this, which involves direct intratumoral injection of magnetic fluids 
into the target region, and then the particles are selectively heated in an externally applied alternating 
magnetic field (AMF). The technique uses the Curie temperature (Tc) of the magnetic material in 
magnetic response heating to achieve automatic temperature control and a constant temperature. Thus 
this technique could avoid overheating of the tissue. In vitro and in vivo experiments with magnetic 
fluids have documented significant antitumor effects in a murine model of liver cancer [1]. Heat also 
enhances the effectiveness of radiotherapy and magnifies the cytotoxicity of many anticancer drugs. 
For this reason, hyperthermic treatment, alone or in combination with traditional anticancer treatments, 
is receiving a great deal of attention. 
Arsenic trioxide (As2O3), a kind of Traditional Chinese Medicine, has drawn researchers’ great 
interest due to its high efficacy in the treatment of acute promyelocytic leukaemia (APL). It also has 
been tested in some solid cancers, such as hepatocellular carcinoma [2], gastric carcinoma [3], breast 
cancer [4], etc. After intravenous or oral administration [5], As2O3 has been accompanied a series of 
side effects, such as skin reactions, gastrointestinal upset, hepatitis and even cardiotoxicity [6]. To 
make the best use of the drug and reduce the harmfulness to the body, it is very important to find a new 
form of As2O3 for clinical therapy. 
In this study, As2O3 was integrated with Mn0.5Zn0.5Fe2O4 nanoparticles, which have super-
paramagnetic characteristics. This feature is quite suitable for use in hyperthermia. On the one hand, a 
certain concentration of magnetic nanoparticles could absorb high power and transform it into heat in  
an alternating magnetic field, while barely damaging peripheric tissue. If used in vivo, the magnetic 
nanoparticles could be inducted in the target region by an external magnetic field. In this way, not only 
does the drug level in the tumor region rise, but also the drug dose decreases. Finally the nanosized 
As2O3/Mn0.5Zn0.5Fe2O4 complex could produce chemotherapy and thermotherapy effects at the   
same time. 
 
2. Results and Discussion 
 
2.1. Characteristics of Mn0.5Zn0.5Fe2O4 Nanoparticles  
 
Figure 1a shows an image of Mn0.5Zn0.5Fe2O4 nanoparticles acquired by TEM. It shows that they 
were nearly spherical, with high electron-density and uniform in size. The X-ray diffraction pattern of 
the ferrite sample is shown in Figure 1b. The observed diffraction lines were found to correspond to 
those of a standard manganese ferrite pattern, thereby indicating that the samples have spinel structure. 
The particle size of the samples had been estimated from the broadening of the X-ray diffraction peaks, 
using the Scherrer equation for Lorentzian peak: d = 0.9 λ/(w-w1)/cosθ. The average particle size was 
found to be between 6 and 22 nm. EDS reports showed At% of Mn, Zn, Fe were 17.58%, 16.44% and 
65.98%, respectively, which is consistent with a molar ratio of 0.5:0.5:1. Figure 2 shows the results of 
thermodynamic test of various doses of Mn0.5Zn0.5Fe2O4 nanoparticles fluid. The nanoparticles were Sensors 2009, 9                  
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dispersed in 0.9% NaCl and exposed to a high-frequency alternating electromagnetic field (output 
current equal to 30 A) for 60 min. As the concentrations of magnetic fluid (MF) increase, its 
temperature rose from 39.5 to 50 °C, and the temperature was stable after exposure to the magnetic 
field for 40 minutes. Our study thus shows that Mn0.5Zn0.5Fe2O4  nanoparticles have powerful 
absorption capabilities in a high-frequency alternating electromagnetic field and strong magnetic 
responsiveness. 
Figure 1. Characterization of Mn0.5Zn0.5Fe2O4.  (a) TEM image of the nanosized 
Mn0.5Zn0.5Fe2O4. (b) XRD of Mn0.5Zn0.5Fe2O4. (c) EDS of Mn0.5Zn0.5Fe2O4. 
   
 
   
 
Figure 2. Heating test curve of sized Mn0.5Zn0.5Fe2O4 nanoparticle fluid. 
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2.2. Cytotoxicity of Mn0.5Zn0.5Fe2O4 Nanoparticles 
 
The morphological changes of L929 cells after treatment with different concentrations of   
Mn0.5Zn0.5Fe2O4 leaching liquor were observed by inverted microscopy. As shown in Figure 3, the 
shapes and growth of the treated cells were similar to that of cells in the negative group. They 
exhibited normal features, such as clear edges, homogeneous staining and no cell fragments, while the 
cells of the positive group became small and globular, and even parts of cells were suspended 48 hours 
later. Only small amounts of cells survived. The results of the MTT assay are shown in Table 1. 
According to RGR and toxicity grade conversion table (see Section 3.3), the toxicity of 
Mn0.5Zn0.5Fe2O4 leaching liquor was classified as grade 1, which was safe to the cells. This is in 
agreement with the findings from inverted microscopy and demonstrated that Mn0.5Zn0.5Fe2O4 didn’t 
show cytotoxicity in vitro. 
Figure 3. Pictures of cytotoxicity evaluation on L929 cells, which were cultured in 
different concentrations of Mn0.5Zn0.5Fe2O4 leaching liquor. (a) Negative group. (b) 25% 
Leaching liquor. (c) 50% Leaching liquor. (d) 75% Leaching liquor. (e) 100% Leaching 
liquor. (f) Positive group. 
       
 
       
 
Table 1. The results of cytotoxicity of Mn0.5Zn0.5Fe2O4 nanoparticles evaluated by MTT 
assay(  ± s, n = 8). 
Groups Optical  Density 
(OD) 
RGR/% Toxicity  Grade 
Negative control group 
25% Mn0.5Zn0.5Fe2O4 leaching liquor 
50% Mn0.5Zn0.5Fe2O4 leaching liquor 
75% Mn0.5Zn0.5Fe2O4 leaching liquor 
100% Mn0.5Zn0.5Fe2O4 leaching 
liquor 
Positive group 
1.035 ± 0.042 
1.017 ± 0.038 
1.006 ± 0.051 
0.973 ± 0.042 
0.952 ± 0.034 
0.229 ± 0.025 
100 
98.3 
97.2 
94.0 
91.9 
22.1 
0 
1 
1 
1 
1 
4 
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2.3. Characterization of the Nanosized As2O3/Mn0.5Zn0.5Fe2O4 Complex 
 
The self-prepared nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex particles are approximately spherical 
and uniform in size (Figure 4). The EDS result confirmed that the prepared complex only contained 
As, Mn, Zn, Fe and O. The envelop rate of As2O3 was 0.260%. The release rate of As2O3 is shown in 
Figure 5. As time elapsed, the release of as increased gradually. 
 
Figure 4. SEM image of the nanosizedAs2O3/Mn0.5Zn0.5Fe2O4. 
 
 
Figure 5. The accumulative release rate of As2O3/Mn0.5Zn0.5Fe2O4 nanoparticles. 
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2.4. Inhibition of HepG2 Proliferation after Treated with Nanosized Complex Combined with MFH 
 
The therapeutic results of the MTT assay are shown in Table 1. The cell growth inhibitory ratio (IR) 
of the As2O3  alone group, the Mn0.5Zn0.5Fe2O4 magnetic nanoparticles group and the nanosized   
As2O3/Mn0.5Zn0.5Fe2O4 complex group were 32.3%, 30.7% and 55.2%, respectively. The negative 
control group and the experimental groups had a great difference (p < 0.05). Due to the combined 
advantages of the thermotherapy and the chemotherapy, the nanosized As2O3/Mn0.5Zn0.5Fe2O4 
complex in combination with MFH could more significantly inhibit the proliferation of the HepG2 
cells compared to the As2O3 alone group and Mn0.5Zn0.5Fe2O4 magnetic nanoparticles in combination 
with MFH group (p  < 0.05). So we may conclude that the therapeutic effect of nanosized 
As2O3/Mn0.5Zn0.5Fe2O4 complex in combination with MFH on HepG2 cells is much better than that of 
As2O3 alone or Mn0.5Zn0.5Fe2O4 in combination with MFH. Sensors 2009, 9                  
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Table 2. Growth inhibitory rate of As2O3/Mn0.5Zn0.5Fe2O4 nanoparticles with MFH on 
HepG2 cells. 
Groups  Optical density (OD)  Inhibitory rate (%) 
Negative control group 
single As2O3group (5μm/L) 
single Mn0.5Zn0.5Fe2O4 group (10g/L) 
As2O3/ Mn0.5Zn0.5Fe2O4 complex group 
1.207 ± 0.071 
0.817 ± 0.024 
0.836 ± 0.034 
0.540 ± 0.037 
0 
32.3% (1) 
30.7% (1) 
55.2% (1) (2) 
Comparison of experimental groups with negative control group; (1) p < 0.05. Comparison of 
nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex group with single As2O3  group and single 
Mn0.5Zn0.5Fe2O4 magnetic nanoparticles combined with MFH group; (2) p < 0.05. 
 
2.5. Nanosized As2O3/Mn0.5Zn0.5Fe2O4 Complex Combined with MFH Induces Apoptosis of HepG2 Cells 
 
The present study disclosed that the combination of thermotherapy and chemotherapy resulted in 
synergistic inhibition of hepatoma [7]. Both As2O3 [8] and ferromagnetic fluid thermotherapy [9] could 
induce apoptosis of HepG2 cells.  
Figure 6. Apoptosis of HepG2 cells induced by the different methods. A) The negative 
control group. the cells of G2 phase account for 13.71.%, the apoptotic rate was 0.42%.  
B) The single As2O3 group the cells of G2 phase account for 44.75%, the apoptotic rate 
was 11.57%. C) The single Mn0.5Zn0.5Fe2O4magnetic nanoparticles group. the cells of G2 
phase account for 36.15%, the apoptotic rate was 13.4%. D) The nanosized As2O3/ 
Mn0.5Zn0.5Fe2O4 complex group. The cells of G2 phase account for 15.9%, the apoptotic 
rate was 27.72%.  
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In our study, the flow cytometry assay showed that the apoptotic indexes of HepG2 cells of the 
single As2O3 group, the single  Mn0.5Zn0.5Fe2O4 magnetic nanoparticles group and the nanosized 
As2O3/Mn0.5Zn0.5Fe2O4 complex group after treatment were 11.57%, 13.48% and 27.72%, 
respectively. However, the apoptotic index of the control group was 0.42%. In the experimental 
groups, we found a significant hypodiploid peak before the G1 phase, which was the apoptotic peak 
(Figure 6). At the same time, there was a prominent cell cycle blockage in the G2/M phase in these 
groups. Other studies also found As2O3 and hyperthermia could arrest the cell cycle at S or G2/M 
phase in tumor cells respectively [9,10], so As2O3/Mn0.5Zn0.5Fe2O4 in combination with MFH could 
induce an obvious cell cycle disturbance and apoptosis. 
 
3. Instruments and Methods 
 
3.1. Preparation and Characterization of Nanosized Mn0.5Zn0.5Fe2O4 Magnetic Nanoparticles 
 
Mn-Zn ferrite of composition Mn0.5Zn0.5Fe2O4 was prepared by the precipitation method (for details 
see [6]). Its shape was observed by H-600 transmission electron microscope (TEM). X-ray diffraction 
(XRD) was used to analyse its crystal structure and diameter. An energy dispersive spectrometer 
(EDS) was employed to assay its composition.  
 
3.2. Heating Test of Nanosized Mn0.5Zn0.5Fe2O4 in vitro 
 
Various doses of Mn0.5Zn0.5Fe2O4  nanoparticles were dispersed in 5 mL 0.9% NaCl, to 
concentrations of 8, 10, 12.5 and 15 g/L, respectively. Then the nanoparticles fluids were placed in a 
flat-bottomed cuvette. This in turn was placed 5 mm from the bottom of the cuvette to the center of 
hyper-thermia-coil of high frequency electromagnetic field (SP-04C, Shenzhen, China). The output 
frequency was 230 KHz and the output current was 30 ampere, heating 1 h and the temperature was 
measured at 5 min intervals. 
 
3.3. The cytotoxicity of Mn0.5Zn0.5Fe2O4 Nanoparticles 
 
The sterile nanoparticles were diffused in PRPMI 1640 medium (containing 10% fetal calf serum) 
for 72 h at 37 °C. After centrifugalization, the supernatant was filtered to get leaching liquor of 100% 
concentration. L929 cells in a 96-well plate, 6,000 cells per well, were treated after 24 hours 
incubation with various concentrations of leaching liquor (100%, 75%, 50% and 25% leaching liquor), 
and incubation was continued for 48 hours. At the same time, cells cultured with RPMI1640 medium 
containing 10% fetal calf serum as the negative control group, and cells with 0.7% polyacrylamide as 
positive group were also prepared. Inverted microscopy was used to observe general morphological 
changes of the L929 cells, then the MTT assay was performed and the OD value was measured at 
492  nm. The cell relative growth rate was calculated as follows: RGR% = OD of experimental 
group/OD of control group × 100%. According to the biological evaluation of medical devices (test for 
in vitro cytotixicity (ISO10993-5:1999, IDT)), the toxicity grade is precise when the experimental 
results show grade 0 and grade 1. The results show grade 2, which needs evaluate by RGR% and the Sensors 2009, 9                  
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morphological changes of cultured cells. The toxicity grade is uncertian when it belongs to   
other grades. 
 
Table 3． The table of RGR and toxicity grade.  
Toxicity grade  Relative growth rate（） RGR%  
Grade0  ≥ 100 
Grade 1  75–99 
Grade 2  50–74 
Grade 3  25–49 
Grade 4  1–24 
Grade 5  0 
 
3.4. Preparation and Characterization of Nanosized As2O3/Mn0.5Zn0.5Fe2O4 Complex 
 
The nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex was prepared using an impregnation process. As2O3 
was purchased from Sigma (St Louis, MI, U.S.A.). Satis quantum Mn0.5Zn0.5Fe2O4  
nanoparticles were added into the solution of As2O3 (0.01 mg/mL, pH = 5, adjusted by acetic acid) 
under ultrasonic sound dispersion conditions. After 30 min standing at 80 °C, the production 
(nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex) was centrifuged at 2,000 g/min for 10 min and rinsed 
twice with absolute alcohol, then dried. Their shape, component and the envelop ratio were measured 
with SEM, EDS and atom spectrophotometer, respectively. Subsequently the release rate of As2O3 was 
measured. One hundred mg of As2O3/Mn0.5Zn0.5Fe2O4 complex were put in a visking bag filter and 
50 mL 0.9% NaCl was placed outside as dialysis mediator. The system was agitated at the speed of 
50 rpm in 37 °C. In first 5 hours, we sampled every 0.5 h intervals and supplemented the same volume 
of 0.9% NaCl. Then we sampled at the following 24, 36 and 48 h, respectively. The amount of As2O3 
of the sample was measured by atom fluorescence spectrometry. 
 
3.5. The Therapeutic Effects on Cultured Hepatocellular Carcinoma Cells-HepG2 
 
The growth of HepG2 cells treated with nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex combined with 
MFH was examined by an MTT assay. HepG2 cells were seeded in a 96-well plate with 6,000 cells per 
well, and after 24 hours incubation they were divided into 4 groups: (1) the negative control group 
(RPMI1640 medium containing 10% fetal calf serum); (2) the As2O3 alone group (5 μM of As2O3);  
(3) the Mn0.5Zn0.5Fe2O4 magnetic nanoparticles combined with MFH group (10 mg/mL); (4) the   
nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex combined with MFH group (the quantity   
of As2O3/Mn0.5Zn0.5Fe2O4 and Mn0.5Zn0.5Fe2O4 was adjusted to 10 mg/mL of Mn0.5Zn0.5Fe2O4 and 
5 μM of As2O3). Each group contained eight wells. The magnetic nanoparticles group and the 
nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex group were treated with MFH for 60 minutes under a high 
frequency alternating electro-magnetic field (f = 230 KHz, I = 30 A). Then incubation of all groups 
was continued for 48 hours, the MTT assay was performed and OD value was measured at 492 nm. Sensors 2009, 9                  
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The cell growth inhibition rate was calculated as follows: (1-OD of experimental group / OD of control 
group)×100%. 
 
3.6. Flow Cytometry Assay 
 
The cells of control group and experimental groups were collected and rinsed in 0.1 PBS   
(pH 7.2–7.4) three times, resuspended and fixed in 70% ethanol at 4 °C overnight. Cells were 
centrifuged and resuspended in 0.1 g/L RNase A at 37 °C for 30 min and in 0.05 g/L propidium iodide 
at 4 °C for 30 min. The cell cycle was analyzed by flow cytometer (FACS Vantage SE, Becton-
Dickson Co). 
 
4. Conclusions 
 
Manganese zinc ferrites (Mn-Zn-Ferrit), a new kind of soft magnetic material, have been widely 
used in biomedicine applications including magnetic resonance, imaging contrast enhancement, tissue 
specific release of therapeutic agents, hyperthermia, and so on. Here, they are chosen for MFH 
according to their high sensitivity of magnetization to temperature and low Tc. From the results of 
characterization of TEM, XRD and EDS, it proved Mn0.5Zn0.5Fe2O4  were successfully prepared 
through an improved coprecipitation process. The prepared Mn0.5Zn0.5Fe2O4 magnetic nanoparticles 
had powerful absorption capabilities in the high frequency alternating magnetic field, rising to a steady 
temperature and showing strong magnetic responsiveness. Mn0.5Zn0.5Fe2O4 magnetic nanoparticles also 
show good biocompatibility, which proved the prepared nanopaticles could be applied in biomedicine. 
As2O3 is a valuable therapeutic tool in hepatoma treatment. Its actions may include its ability to 
induce cellular apoptosis [11–15], inhibit tumor metastasis [16], decrease the expression of vascular 
endothelial growth factor (VEGF) [17,18], enhance immune function [19], and so on. On the other 
hand it lacks targeting ability, and produces some adverse reactions. This limits its application in solid 
cancers. To resolve the problems, a nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex of As2O3 has also been 
prepared. From this study, nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex can be successfully prepared 
through an impregnation process and As2O3 can be released gradually from this As2O3/Mn0.5Zn0.5Fe2O4 
complex. 
The thermochemotherapy of nanosized As2O3/Mn0.5Zn0.5Fe2O4 complex can significantly inhibit the 
proliferation of cultured hepatocellular cancer cells (HepG2) and induced apoptosis and cell cycle 
arrest when combined with magnetic fluid hyperthermia. This indicates that hyperthermia and   
chemotherapy could play a synergistic role. The mechanisms may be: 1) heat could make drug 
absorption increase due to the addition of blood flow in tumor region; 2) heat could decrease the tumor 
vessel regeneration for the reduction of synthesis and secretion of VEGF; 3) heat could enhance the 
cytotoxic effects of the chemotherapeutic drug. We have not confirmed these details, but this study 
may provide a new method for hepatocellular cancer therapy. However, a lot of work needs to be done 
if it is to be applied in clinical treatment. 
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